Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

BF-200 ALA

Aliases
Ameluz, BF-200 ALA and red light LED lamp
Name
AMELUZ
INN Name
aminolevulinic acid hydrochloride
FDA Approved
Yes

4 clinical trials

1 organization

4 indications

1 document

Indication
Actinic Keratosis
Indication
Keratosis
Indication
Actinic
Indication
Basal Cell Carcinoma
Clinical trial
A Randomized, Double-blind, Vehicle-controlled, Multicenter Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using the BF-RhodoLED® XL or BF-RhodoLED® Lamp
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Double-blind, Phase III, Multi-center Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) Versus Placebo in the Field-directed Treatment of Mild to Moderate Actinic Keratosis With Photodynamic Therapy (PDT) When Using the BF-RhodoLED® Lamp
Status: Completed, Estimated PCD: 2014-09-01
Clinical trial
A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BF-200 ALA (Ameluz®) in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp With Photodynamic Therapy (PDT)
Status: Completed, Estimated PCD: 2023-04-20
Clinical trial
A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)
Status: Completed, Estimated PCD: 2015-11-17
Document
DailyMed Label: AMELUZ
Organization
Biofrontera Inc.